|
|
||||||||
Rapid Communication |
Central Laboratory for Clinical Investigation, Osaka University Hospital, 215 Yamadaoka, Suita, Osaka 565-0871, Japan
1 Department of Laboratory Medicine, Osaka University Medical School, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
2 Kuma Hospital, Simoyamate-Dori, Chuo-Ku, Kobe, Hyogo 650-0011, Japan
(Requests for offprints should be addressed to I Maeda; Email: maeda{at}hp-lab.med.osaka-u.ac.jp)
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
In a previous study, we developed a modified method of differential display, sequence specific-differential display (SS-DD), which allows the rapid screening of specific changes in mRNAs in tumor tissues (Takano et al. 1997). In SS-DD, a 16- to 18-base degenerate primer instead of a 10-mer primer is used to prevent false positive results by performing the polymerase chain reaction (PCR) with a high annealing temperature. In addition, Ex-Taq polymerase instead of Taq polymerase is used to produce longer PCR products, which helps to avoid amplification of the 3' non-coding region.
Using SS-DD, we have detected three genes in which the expression levels were higher in normal thyroid tissues than in thyroid tumor tissues. One of these genes was identified as acid ceramidase, but the other two genes showed unknown sequences (Maeda et al. 1999). We cloned one of these unknown genes and found that it is identical to the genes named tensin3 (Cui et al. 2004) or TEM6 (Carson-Walter et al. 2001) in other studies. Interestingly, in human tissues, this gene is expressed in the thyroid in a restricted manner, which suggests it is a novel thyroid-specific gene.
| Materials and methods |
|---|
|
|
|---|
Tissue samples were obtained at surgery, and were quickly frozen in liquid nitrogen. Total RNA was extracted according to a method described previously (Chomczynski & Sacchi 1987). All tissues were histologically classified according to WHO guidelines (Hedinger et al. 1989). The study protocol was approved by the institutional ethical committee. Informed consent was obtained from all patients.
Sequence specific-differential display
SS-DD was performed essentially as previously described (Takano et al. 1997). In brief, RNAs from nine normal thyroid tissue samples, five papillary carcinomas, two follicular adenomas and two follicular carcinomas were used for the screening using SS-DD. All primers were purchased from Funakoshi (Tokyo, Japan). DNase digestion of 10 µg total RNA was performed with DNase I (Takara, Sigma, Kyoto, Japan), at 37 °C for 30 min. The RNA pellet was phenol/chloroform/isoamyl alcohol-extracted, and was precipitated with ethanol, followed by reconstitution with distilled water. Two micrograms total RNA were converted to cDNA in an reverse transcriptase (RT) mixture containing 8 µl 5xRT buffer, 8 µl 2.5 mM deoxynucleosidetriphosphate (dNTP) (Takara), 0.4 µl 100 mM dithiothreitol, 2 µl 200 U/µl reverse transcriptase (Gibco, Gaithersburg, MD, USA), 0.4 µl 140 µU/µl RNase inhibitor (Takara), and 200 µM oligo dT (Funakoshi) in a total volume of 40 µl (adjusted adding nuclease-free water) at 37 °C for 60 min. Two degenerate primers were used in the following PCR. One, SH2 (2.0 µM): 5'-TTCCTGGTG(A/C)G(A/G)(G/C)A(G/C)(A/T/U) (G/C)-3', was based on the consensus sequence for the Src homology 2 (SH2) domain (Matuoka et al. 1992), and the other, DD3'-2 (2.0 µM): 5'-GTTTTTTTTTTT TTTTTTTT(G/A/C)-3', was designed to anneal to the poly A tail. Each reaction mixture consisted of 1 µl cDNA, 200 µM of each primer, 4 µl 10xEx Taq buffer, 4 µl 2.5 mM dNTP mix, 2 U Ex Taq polymerase, and nuclease-free water to a final volume of 40 µl; 10xEx Taq buffer, 2.5 mM dNTP mix, and Ex Taq polymerase were obtained from Takara. The PCR was performed at 94 °C for 2 min, then 2 cycles of denaturation (94 °C, 1 min), annealing (40 °C, 3 min) and extension (72 °C, 5 min), followed by 40 cycles of denaturation (94 °C, 1 min), annealing (55 °C, 1 min) and extension (72 °C, 2 min with 5 s of auto-segment extension for each cycle). After PCR amplification, 4.0 µl reaction mixture were run on a 3.5% acrylamide gel in a TrisHCl/boric acid/EDTA (TBE) buffer (pH 8.0) using 360-mm glass sequencing plates (Takara). After electrophoresis, one of the glass plates was removed, and the gel was stained with SYBR Green I (Wako, Osaka, Japan) and analyzed with a Fluor Imager (Molecular Dynamics, Sunnyvale, CA, USA). The bands of interest were cut with a razor, and PCR products were extracted by boiling at 100 °C for 5 min. The PCR products were amplified by PCR with the following two primers: SH2-R (2.0 µM): 5'-ATGCGAATTCTTTCCTGGTG (A/C)G(A/G)(G/C) A-3'and DD3'-R2 (0.5 µM): 5'-ATG CGAATTCGTTTTTTTTTTTTTTTTTTT-3'in a reaction mixture containing 5 µl 10xEx Taq buffer, 4 µl 2.5 mM dNTP mix, 2.5 U Ex Taq polymerase and nuclease-free water to a final volume of 50 µl. The PCR was carried out for 30 cycles at 94 °C, 60 °C and 72 °C for 1 min. Purified PCR products were cloned into a pMOSBlue vector using a pMOSBlue T-vector kit (Amersham, Bucks, UK) according to the manufacturers instructions. DNA sequencing was performed using a Taq Dye Primer Cycle Sequencing Kit and a 373 A DNA sequencer (Perkin-Elmer, Foster City, CA, USA).
Cloning of an unknown gene
Cloning of an unknown gene was carried out using a human thyroid cDNA library (Takara) with hybridization analysis. A cDNA fragment for hybridization was amplified from a human thyroid cDNA with RT-PCR using the following two primers: 5SN1SC (0.5 µM): 5'-TTCCTGTCCCACAACTTTCTCACG-3' (base 32023225 of tensin3 cDNA), and 3SN1SC (0.5 µM): 5'-ATATCCGCCTTGTACCAGAACTTG-3' (base 35163539 of tensin3 cDNA). The amplified probe was labeled with an AlkPhos labeling kit and the CDP-Star detection reagent (Amersham Pharmacia Biotech, UK) was used for signal detection. Hybridization and detection were performed according to the manufacturers protocol.
Reverse transcription-PCR
Reverse transcription-PCR (RT-PCR) was performed as previously described (Takano et al. 1997). cDNAs from four thyroid tissue samples and human cDNAs (Clontech, Palo Alto, CA, USA) from brain, heart, lung, liver, pancreas, kidney, placenta, skeletal muscle, white blood cells (WBC) and prostate were analyzed. The following primers were used for the PCR: one was 5SN1SC (0.5 µM): 5'-TTCCTGTCCCACAACTTTC TCACG-3' (base 32023225 of tensin3 cDNA (GenBank AF417489 [GenBank] )), and the other was 3SN1SC (0.5 µM): 5'-ATATCCGCCTTGTACCAGAACTTG-3' (base 35163539 of tensin3 cDNA). The PCR was performed at 95 °C for 10 min, and 35 cycles of 95 °C, 60 °C and 72 °C for 30 s. Four microliters of each PCR product were electrophoresed on a 1.5% SeaKem GTG agarose gel (Takara) in a TrisHCl/acetate/EDTA (pH 8.0) buffer. The gel was stained with ethidium bromide, then analyzed with a Fluor Imager.
Real-time quantitative RT-PCR of tensin3 mRNA
Real-time quantitative RT-PCR (TaqMan RT-PCR) using the ABI PRISM 7700 Sequence Detection System (Perkin-Elmer) was performed according to the manufacturers protocol. The amplified sequence was different from that amplified in the RT-PCR analysis. The two primers and one TaqMan probe used for the quantification of tensin3 mRNA were: 5 TMSN1 (0.5 µM): 5'-CATATTTCGGGAGCCTGACG-3' (base 37733792), 3 TMSN1 (0.5 µM): 5'-TCAAGTACCAC ACATTGCAG-3' (base 39403958), and SN1-TM (10 pmol): 5'-FAM-CAGAGAGAGATCCATTGGAG GAA-TAMRA-3' (base 38513873). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (GenBank BC013310 [GenBank] ) was used as an internal control since the expression levels of GAPDH mRNA in normal thyroid tissues, follicular adenomas, papillary carcinomas and follicular carcinomas were almost equal (Takano et al. 2000). The two primers and one TaqMan probe used for the quantification of GAPDH were: TMGPD5 (0.5 µM): 5'-TCCATGACAACTTTGGTATC-3' (base 551570), TMGPD3 (0.5 µM): 5'-AAGGTCATCCCT GAGCTAGA-3' (base 715734), and GPD-TM (10 pmol): 5'-FAM-AGAACATCATCCCTGCCTCTA CT-TAMRA-3' (base 671693). The analyzed cDNAs were reverse-transcribed from RNAs extracted from 28 normal thyroid tissues, 13 follicular adenomas, 10 adenomatous goiters, 15 papillary carcinomas, 5 follicular carcinomas and 2 anaplastic carcinomas, as described above. Human cDNAs (Clontech) from brain, heart, lung, liver, pancreas, kidney, placenta, skeletal muscle, WBC and prostate were also analyzed. The conditions for the TaqMan RT-PCR were as follows: 95 °C for 10 min and 40 cycles of 95 °C for 15 s, and 60 °C for 1 min. Recombinant pGEM T-vectors (Promega, Tokyo, Japan) containing either tensin3 or GAPDH cDNA were constructed by PCR-cloning with the same sets of primers used in the TaqMan RT-PCR, and were used as standard samples.
Statistical analysis
The Mann-Whitney test was used to determine differences between the tensin3 mRNA/GAPDH mRNA of normal thyroid tissues and that of thyroid tumors. P values of less than 0.05 were considered to be significant.
Analysis of the SAGE database
A tag counting analysis based on the SAGE libraries was performed with the public database (http://www.ncbi.nlm.nih.gov/projects/SAGE/index.cgi?cmd=tagsearch).
| Results |
|---|
|
|
|---|
In the results of electrophoresis, three bands, SN1, SN2 and SN3, which decrease in tumor tissues, were observed (Fig. 1
). A band of SN1 was cut out from the gel, and the extracted PCR products were then reamplified with PCR with the primers, SH2R and DD3'-R2. The reamplified PCR products were cloned into a pMOSBlue vector, and sequencing analysis was carried out. The sequence of SN2 corresponded to the 14822330 bp position of acid ceramidase mRNA (Maeda et al. 1999). The other two clones showed no homology to known sequences.
|
Using a human thyroid cDNA library, we screened about 10 000 clones, and found 3 positive clones. The detected clones were 5076 bp and had a huge 3' non-coding region. The predicted amino acid sequence showed the existence of an SH2 domain and a phosphotyrosine binding (PTB) domain. Thus, we named this gene the thyroid-specific PTB domain protein (TPP) (GenBank AB062750
[GenBank]
). This gene has also been cloned by two other groups. Carson-Walter et al.(2001) named it TEM6 (GenBank AF3787560) and Cui et al.(2004) named it tensin3 (GenBank AF417489
[GenBank]
). The comparison of these three reported sequences is summarized in Fig. 2
. The coding region of tensin3 mRNA is the longest, 1445 amino acid residues, among the three genes.
|
Quantitative analysis of tensin3 mRNA
To confirm the decreased expression of tensin3 mRNA in thyroid tumors, TaqMan RT-PCR was carried out. The expression levels of tensin3 mRNA were decreased in papillary carcinomas, follicular carcinomas and follicular adenomas. It expression was decreased markedly in the 2 anaplastic carcinomas (Fig. 3
).
|
To confirm the specific restricted expression of tensin3 mRNA in the thyroid, semi-quantitative RT-PCR was carried out using cDNAs from the brain, heart, lung, liver, pancreas, kidney, placenta, skeletal muscle, WBC and prostate. As shown in Fig. 4
, tensin3 mRNA was expressed at high levels in thyroid tissues. Moderate expression of tensin3 was observed in the placenta and it was only weakly expressed in other tissues.
|
Based on the sequence of TPP mRNA, the following ten bases after the last CATG in the 3'-noncoding region are TTAAAAGTCA. There were only six libraries from normal human tissues with this tag (Table 1
). The tag count was high in the thyroid and placenta, which is identical to the result obtained with RT-PCR.
|
| Discussion |
|---|
|
|
|---|
TEM6 was first reported by St Croix et al. in 2000. They identified 46 transcripts named TEMs (tumor endothelial markers), which were significantly up-regulated in tumors compared with normal endothelium. However, they did not undertake further study on the TEM6 gene.
In the present study, we confirmed the overexpression of tensin3 mRNA in the human thyroid. Tensin3 mRNA was also expressed in thyroid tumors, although its expression levels were much lower in tumor tissues and even lower in anaplastic carcinomas. The restricted expression of tensin3 in the thyroid was confirmed by both quantitative RT-PCR and the SAGE database analysis. In the SAGE database analysis, the SAGE tag was also detected in the prostate, placenta, lung, kidney, liver and heart. However, in three of these six libraries, the corresponding tag sequence appeared only once, which suggests the possibility that the expression levels of tensin3 in these tissues are much lower than those expected from the data of tags per million.
The role of tensin3 in the thyroid cell is not clear. Chiang et al.(2005) generated mutant mice with a disrupted tensin3 gene and suggested that the tensin3 gene might be related to a sub-population of Silver-Russell syndrome patients. Interestingly, although Chiang et al. did not examine the thyroids or thyroid function in these mice, the mice were distinct dwarves, which suggest the existence of inherited hypothyroidism.
Finally, the results of our presented study show that tensin3 mRNA is expressed in a restricted manner in the human thyroid. This fact suggests that tensin3 may play some fundamental role in thyroid function and may relate to some thyroid diseases, as do the other thyroid-specific genes such as TPO, TG, NIS and TSHR.
| Acknowledgements |
|---|
| References |
|---|
|
|
|---|
Carson-Walter EB, Vogelstein B, Kinzler KW & St Croix B 2001 Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Research 61 66496655.
Chen H, Duncan IC, Bozorgchami H & Lo SH 2002 Tensin1 and a previously undocumented family member, tensin2, positively regulate cell migration. PNAS 99 733738.
Chiang MK, Liao YC, Kuwabara Y & Lo SH 2005 Inactivation of tensin3 in mice results in growth retardation and postnatal lethality. Developmental Biology 279 368377.[CrossRef][ISI][Medline]
Chomczynski P & Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162 156159.[ISI][Medline]
Cui Y, Liao Y & Lo SH 2004 Epidermal growth factor modulates tyrosine phosphorylation of novel tensin family member, tensin3. Molecular Cancer Research 2 225232.
Haddad HM & Sidbury JB Jr 1959 Defect of the iodinating system in congenital goitrous cretinism: report of a case with biochemical studies. Journal of Clinical Endocrinology 19 14461457.
Hedinger C, Williams ED & Sobin LH 1989 The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63 908911.[CrossRef][ISI][Medline]
Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S & Schlumberger M 1999 Expression of the Na(+)/I() symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. Journal of Clinical Endocrinology and Metabolism 84 32283234.
Lo SH & Lo TB 2002 Cten, a COOH-terminal tensin-like protein with prostate restricted expression, is down-regulated in prostate cancer. Cancer Research 62 42174221.
Maeda I, Takano T, Matsuzuka F, Maruyama T, Higashiyama T, Liu G, Kuma K & Amino N 1999 Rapid screening of specific changes in mRNA in thyroid carcinomas by sequence specific-differential display: decreased expression of acid ceramidase mRNA in malignant and benign thyroid tumors. International Journal of Cancer 81 700704.[CrossRef]
Matuoka K, Shibata M, Yamakawa A & Takenawa T 1992 Cloning of ASH, a ubiquitous protein composed of one src homology region (SH) 2 and two SH3 domains, from human and rat cDNA libraries. PNAS 89 90159019.
Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL & Jhiang SM 1996 Cloning of the human sodium iodide symporter. Biochemical and Biophysical Research Communications 226 339345.[CrossRef][ISI][Medline]
St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B & Kinzler KW 2000 Genes expressed in human tumor endothelium. Science 289 11971202.
Takano T, Matsuzuka F, Sumizaki H, Kuma K & Amino N 1997 Rapid detection of specific messenger RNAs in thyroid carcinomas by reverse transcription-PCR with degenerate primers: specific expression of oncofetal fibronectin messenger RNA in papillary carcinoma. Cancer Research 57 37923797.
Takano T, Hasegawa Y, Matsuzuka F, Miyauchi A, Yoshida H, Higashiyama T, Kuma K & Amino N 2000 Gene expression profiles in thyroid carcinomas. British Journal of Cancer 83 14951502.[CrossRef][ISI][Medline]
Received in final form 7 November 2005
Accepted 2 December 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |